Fidarestat is a selective inhibitor of the mitochondrial farnesyltransferase enzyme that functions as an anti-cancer agent targeting protein prenylation pathways. Primarily investigated for its potential… Read more
Fidarestat is a selective inhibitor of the mitochondrial farnesyltransferase enzyme that functions as an anti-cancer agent targeting protein prenylation pathways. Primarily investigated for its potential in treating leukemia and solid tumors, this compound works by blocking the attachment of farnesyl groups to key oncoproteins such as Ras. Laboratories working with this drug require high-quality reference standards for rigorous analytical testing and method validation. The category includes stable isotope-labelled compounds like fidarestat-d3, which are essential for mass spectrometry-based quantitative analysis. By functioning as internal standards, these labelled analogues enable precise impurity profiling and support consistent quality control testing, ensuring the accuracy and reliability of pharmacokinetic and clinical studies conducted during pharmaceutical development.